FDA Grants IDE Approval for OCS Heart ENHANCE Trial
Andover, Massachusetts | February 9, 2026 — TransMedics Group has received full and unconditional Investigational Device Exemption (IDE) approval...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Andover, Massachusetts | February 9, 2026 — TransMedics Group has received full and unconditional Investigational Device Exemption (IDE) approval...
Oxford, England, and Madison, New Jersey, October 30, 2025 — Terumo Corporation, a global leader in medical technology, has...
DULUTH, Ga., Oct. 7, 2025 — Bridge to Life Ltd. has received FDA 510(k) clearance for its multi-sourced Belzer...
